参考文献/References:
[1] Libby P. The changing landscape of atherosclerosis[J]. Nature,2021,592(7855):524-533.
[2] Schanbacher C,Hermanns HM,Lorenz K,et al. Complement 1q/tumor necrosis factor-related proteins(CTRPs):structure,receptors and signaling[J]. Biomedicines,2023,11(2):559.
[3] Moriya J. Critical roles of inflammation in atherosclerosis[J]. J Cardiol,2019,73(1-2):22-27.
[4] Jinnouchi H,Guo L,Sakamoto A,et al. Diversity of macrophage phenotypes and responses in atherosclerosis[J]. Cell Mol Life Sci,2020,77(10):1919-1932.
[5] Blagov AV,Markin AM,Bogatyreva AI,et al. The role of macrophages in the pathogenesis of atherosclerosis[J]. Cells,2023,12(4):522.
[6] Durham AL,Speer MY,Scatena M,et al. Role of smooth muscle cells in vascular calcification:implications in atherosclerosis and arterial stiffness[J]. Cardiovasc Res,2018,114(4):590-600.
[7] Wang Y,Li H,Yu XH,et al. CTRP1:a novel player in cardiovascular and metabolic diseases[J]. Cytokine,2023,164:156162.
[8] Zhang ZZ,Chen JJ,Deng WY,et al. CTRP1 decreases ABCA1 expression and promotes lipid accumulation through the miR-424-5p/FoxO1 pathway in THP-1 macrophage-derived foam cells[J]. Cell Biol Int,2021,45(11):2226-2237.
[9] Si YQ,Fan WJ,Sun LX. A review of the relationship between CTRP family and coronary artery disease[J].Curr Atheroscler Rep,2020,22(6):22.
[10] Hofmann C,Chen N,Obermeier F,et al. C1q/TNF-related protein-3(CTRP-3) is secreted by visceral adipose tissue and exerts antiinflammatory and antifibrotic effects in primary human colonic fibroblasts[J]. Inflamm Bowel Dis,2011,17(12):2462-2471.
[11] Guo SR,Mao XH,Liu J. Multi-faceted roles of C1q/TNF-related proteins family in atherosclerosis[J].Front Immunol,2023,14:11.
[12] Chen L,Qin LJ,Liu X,et al. CTRP3 Alleviates Ox-LDL-induced inflammatory response and endothelial dysfunction in mouse aortic endothelial cells by activating the PI3K/Akt/eNOS pathway[J]. Inflammation,2019,42(4):1350-1359.
[13] Mei J,Gui JF. Bioinformatic identification of genes encoding C1q-domain-containing proteins in zebrafish[J]. J Genet Genomics,2008,35(1):17-24.
[14] Wang L. CTRP4:a new member of the adipocytokine family[J]. Cell Mol Immunol,2017,14(10):868-870.
[15] Cho WJ,Oh H,Choi SW,et al. CTRP4 attenuates apoptosis and epithelial-mesenchymal transition markers in podocytes through an AMPK/autophagy-dependent pathway[J]. Biochem Biophys Res Commun,2023,682:104-110.
[16] Cao LL,Tan WF,Chen W,et al. CTRP4 acts as an anti-inflammatory factor in macrophages and protects against endotoxic shock[J]. Eur J Immunol,2021,51(2):380-392.
[17] Li C,Chen JW,Liu ZH,et al. CTRP5 promotes transcytosis and oxidative modification of low-density lipoprotein and the development of atherosclerosis[J]. Atherosclerosis,2018,278:197-209.
[18] Liu J,Meng ZJ,Gan L,et al. C1q/TNF-related protein 5 contributes to diabetic vascular endothelium dysfunction through promoting Nox-1 signaling[J]. Redox Biol,2020,34:101476.
[19] Chi LY,Hu XJ,Zhang WT,et al. Adipokine CTRP6 improves PPARγ activation to alleviate angiotensin Ⅱ-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats[J]. Biochem Biophys Res Commun,2017,482(4):727-734.
[20] Dong XZ,Hu HJ,Fang ZD,et al. CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration[J]. Biomed Pharmacother,2018,103:844-850.
[21] Liu JL,Yan XN,Wang ZL,et al. Adipocyte factor CTRP6 inhibits homocysteine-induced proliferation,migration,and dedifferentiation of vascular smooth muscle cells through PPARγ/NLRP3[J]. Biochem Cell Biol,2021,99(5):596-605.
[22] Zeng M,Wei X,He YL,et al. Ubiquitin-specific protease 11-mediated CD36 deubiquitination acts on C1q/TNF-related protein 9 against atherosclerosis[J]. ESC Heart Fail,2023,10(4):2499-2509.
[23] Zhang H,Gong XY,Ni SM,et al. C1q/TNF-related protein-9 attenuates atherosclerosis through AMPK-NLRP3 inflammasome singling pathway[J]. Int Immunopharmacol,2019,77:105934.
[24] Chen JY,Lei SY,Li TT,et al. CTRP9 induces iNOS expression through JAK2/STAT3 pathway in Raw 264.7 and peritoneal macrophages[J]. Biochem Biophys Res Commun,2020,523(1):98-104.
[25] Zhang L,Liu Q,Zhang H,et al. C1q/TNF-related protein 9 inhibits THP-1 macrophage foam cell formation by enhancing autophagy[J]. J Cardiovasc Pharmacol,2018,72(4):167-175.
[26] Scheja L,Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease[J]. Nat Rev Endocrinol,2019,15(9):507-524.
[27] Guan H,Wang YL,Li XY,et al. C1q/tumor necrosis factor-related protein 9:basics and therapeutic potentials[J].Front Physiol,2022,13:816218.
[28] Chen JY,Song CX,Lei SY,et al. CTRP9 induces macrophages polarization into M1 phenotype through activating JNK pathway and enhances VSMCs apoptosis in macrophages and VSMCs co-culture system[J]. Exp Cell Res,2020,395(1):112194.
[29] Tan SY,Lei X,Little HC,et al. CTRP12 ablation differentially affects energy expenditure,body weight,and insulin sensitivity in male and female mice[J]. Am J Physiol Endocrinol Metab,2020,319(1):E146-E162.
[30] Wang G,Chen JJ,Deng WY,et al. CTRP12 ameliorates atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory response via the miR-155-5p/LXRα pathway[J]. Cell Death Dis,2021,12(3):254.
[31] Wang C,Xu WJ,Liang ML,et al. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36[J]. FASEB J,2019,33(2):2290-2300.
[32] Guan H,Shi T,Liu MM,et al. C1QL1/CTRP14 is largely dispensable for atherosclerosis formation in apolipoprotein-e-deficient mice[J]. J Cardiovasc Dev Dis,2022,9(10):341.
[33] Seldin MM,Peterson JM,Byerly MS,et al. Myonectin(CTRP15),a novel myokine that links skeletal muscle to systemic lipid homeostasis[J]. J Biol Chem,2012,287(15):11968-11980.
[34] Tan WH,Peng ZL,You T,et al. CTRP15 promotes macrophage cholesterol efflux and attenuates atherosclerosis by increasing the expression of ABCA1[J]. J Physiol Biochem,2022,78(3):653-666.
[35] Lu L,Zhang RY,Wang XQ,et al. C1q/TNF-related protein-1:an adipokine marking and promoting atherosclerosis[J]. Eur Heart J,2016,37(22):1762-1771.
[36] Shen LH,Wang SH,Ling Y,et al. Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease[J]. J Int Med Res,2019,47(6):2571-2579.
[37] Zhang H,Zhang-Sun ZY,Xue CX,et al. CTRP family in diseases associated with inflammation and metabolism:molecular mechanisms and clinical implication[J]. Acta Pharmacol Sin,2023,44(4):710-725.
[38] Choi KM,Hwang SY,Hong HC,et al. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris[J]. Cardiovasc Diabetol,2014,13:14.
[39] Dai YL,Zhou J,Niu LJ,et al. Increased serum C1q/TNF-related protein 4 concentration in patients with acute coronary syndrome[J]. Clin Chim Acta,2022,524:187-191.
[40] Gao J,Lu J,Qiu JH,et al. C1q tumor necrosis factor-related protein 4 is associated with coronary artery disease in patients with type 2 diabetes[J]. J Diabetes Investig,2022,13(10):1723-1731.
[41] Liu YL,Wang XB,Wang T,et al. Retracted:relationship between coronary VH-IVUS plaque characteristics and CTRP9,SAA,and Hcy in patients with coronary heart disease (retracted article)[J]. J Healthc Eng,2023,2023:9859038.
[42] Nahrkhalaji AS,Ahmadi R,Fadaei R,et al. Higher serum level of CTRP15 in patients with coronary artery disease is associated with disease severity,body mass index and insulin resistance[J]. Arch Physiol Biochem,2022,128(1):276-280.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(6):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(6):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(6):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]